Scopes of Bioanalytical Chromatography-Mass Spectrometry

被引:2
作者
Savelieva, E., I [1 ]
机构
[1] Fed Med Biol Agcy, Res Inst Hyg Occupat Pathol & Human Ecol, Leningrad Oblast 188663, Vsevolozhskii R, Russia
基金
英国科研创新办公室;
关键词
bioanalytics; chromatography-mass spectrometry; biomarker; exposome; metabolic status; coronavirus infection; PERSISTENT ORGANIC POLLUTANTS; DNA-DAMAGE; URINARY; SERUM; METABOLITES; EXERCISE; ADDUCTS; SAMPLES; POPS; MS;
D O I
10.1134/S106193482108013X
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The areas of application of modern bioanalytical chromatography-mass spectrometry are so extensive that any attempt to systematize them becomes subjective. It would be more correct to say that there is no such area of biology and medicine where chromatography-mass spectrometry would not find application. This article focuses on the areas of application of this technique that are either relatively new or insufficiently covered in recent reviews. State-of-the-art bioanalytical techniques have become multitargeted in terms of analytes and standardized in terms of matrices. The ability to detect trace concentrations of analytes in the presence of a huge number of biomatrix macrocomponents using chromatography-mass spectrometry is especially important for bioanalytical chemistry. In the target-oriented determination of persistent organic pollutants by chromatography-mass spectrometry, the main problem is the expansion of the list of analytes, including isomers. In the detection of exposures to unstable toxicants, the fragmented adducts of xenobiotics with biomolecules become target biomarkers along with hydrolytic metabolites. The exposome reflects the general exposure of a human being to total xenobiotics and the metabolic status reflects the physiological state of the body. Chromatography-mass spectrometry is a key technique in metabolomics. Metabolomics is currently used to solve the problems of clinical diagnostics and anti-doping control. Biological sample preparation procedures for instrumental analysis are being simplified and developed toward increasing versatility. Proteomic technologies with the use of various versions of mass spectrometry have found application in the development of new methods for diagnosing coronavirus infections.
引用
收藏
页码:1198 / 1210
页数:13
相关论文
共 101 条
[1]   A pilot study comparing the metabolic profiles of elite-level athletes from different sporting disciplines [J].
Al-Khelaifi, Fatima ;
Diboun, Ilhame ;
Donati, Francesco ;
Botre, Francesco ;
Alsayrafi, Mohammed ;
Georgakopoulos, Costas ;
Suhre, Karsten ;
Yousri, Noha A. ;
Elrayess, Mohamed A. .
SPORTS MEDICINE-OPEN, 2018, 4
[2]  
Amirova Z.K., 2016, NOVYE STOIKIE ORGANI, P94
[3]  
Anawalt B., 2000, Performance enhancing hormone doping in sport
[4]   Trends in the application of high-resolution mass spectrometry for human biomonitoring: An analytical primer to studying the environmental chemical space of the human exposome [J].
Andra, Syam S. ;
Austin, Christine ;
Patel, Dhavalkumar ;
Dolios, Georgia ;
Awawda, Mahmoud ;
Arora, Manish .
ENVIRONMENT INTERNATIONAL, 2017, 100 :32-61
[5]   The Potential Role of Oral Fluid in Antidoping Testing [J].
Anizan, Sebastien ;
Huestis, Marilyn A. .
CLINICAL CHEMISTRY, 2014, 60 (02) :307-322
[6]  
[Anonymous], 2013, ANALITIKA
[7]  
[Anonymous], 2020, WADA Technical Document TD2021EAAS: Measurement and Reporting of Endogenous Anabolic Androgenic Steroid (EAAS) Markers of the Urinary Steroid Profile
[8]   Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients [J].
Armstrong, Christopher W. ;
McGregor, Neil R. ;
Lewis, Donald P. ;
Butt, Henry L. ;
Gooley, Paul R. .
METABOLOMICS, 2015, 11 (06) :1626-1639
[9]   NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome [J].
Armstrong, Christopher W. ;
McGregor, Neil R. ;
Sheedy, John R. ;
Buttfield, Ian ;
Butt, Henry L. ;
Gooley, Paul R. .
CLINICA CHIMICA ACTA, 2012, 413 (19-20) :1525-1531
[10]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95